Lilly, CureVac Ink $1.795B+ mRNA Cancer Vaccine Collaboration

Eli Lilly will partner to develop and commercialize up to five cancer vaccines based on CureVac's RNActive ® technology, the companies said today, through a collaboration that could generate up to $1.795 billion-plus for CureVac.The companies plan to use RNActive to deliver mRNA that directs the human immune system to target neoantigens across multiple tumor types. These neoantigens, which are tumor-specific, in turn direct the patient's existing immune system to mount a selective and potent